Washington, DC 20006-5349
HELPLINE
Watch Mary Hesdorffer, the Meso Foundation’s executive director and mesothelioma expert, in this opening presentation at the 2015 International Symposium on Malignant Mesothelioma. In this…
The Meso Foundation is optimistic about the results of the Phase 1b trial of pembrolizumab for PD-L1-positive advanced solid tumors, which were announced at the…
Marjorie Zauderer, MD, is a medical oncologist at Memorial Sloan Kettering Cancer Center specializing in the care of lung cancer and mesothelioma patients, and serves…
by Mary Hesdorffer, NP, Executive Director, Meso Foundation Through our peer reviewed research grant program, the Meso Foundation supports the most promising research projects in…
by Lee Krug, MD, Memorial Sloan Kettering Cancer Center This month, a notification was sent to investigators on the DETERMINE Trial that accrual will be…
***The Best of iMig 2014 updates were created by iMig and distributed to conference attendees during iMig 2014. The following is a verbatim re-post of…
***The Best of iMig 2014 updates were created by iMig and distributed to conference attendees during iMig 2014. The following is a verbatim re-post of…
***The Best of iMig 2014 updates were created by iMig and distributed to conference attendees during iMig 2014. The following is a verbatim re-post of…
Mary Hesdorffer, NP, the executive director of the Meso Foundation is in attendance at the International Mesothelioma Interest Group (iMig) conference in Cape Town, South…
Mary Hesdorffer, MS, APRN-BC, the executive director of the Meso Foundation, will be presenting at the 12th International Mesothelioma Interest Group (iMig) Conference in Cape…
